SCHEMBL5209967

SCHEMBL5209967

CCCCS(=O)(=O)N(C(=O)OC(C)(C)C)c1cc(OC[C@H]2CO2)ccc1OCc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
AR P10275 1/20 0.36
APP P05067 2/20 0.35
PSEN1 P49768 3/20 0.35
PTGES O14684 2/20 0.35
ALOX5 P09917 2/20 0.35
PPARG P37231 2/20 0.35
FFAR1 O14842 1/20 0.35
KCNE1 P15382 2/20 0.35
KCNQ1 P51787 2/20 0.35
GHSR Q92847 3/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
HIF1A Q16665 1/20 0.33
ELOVL6 Q9H5J4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3290077 1.00 MEN1 (0.36) MEN1KMT2AARAPPPSEN1
SCHEMBL5679194 0.95 MEN1 (0.37) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL6552283 0.95 MEN1 (0.37) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL5263054 0.90 MEN1 (0.39) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL3287419 0.90 MEN1 (0.39) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL3142761 0.89 MEN1 (0.40) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL5203422 0.89 MEN1 (0.40) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL3142767 0.89 MEN1 (0.40) MEN1KMT2AAPPPPARGFFAR1
SCHEMBL5264076 0.87 KEAP1 (0.40) MEN1KMT2AAPPFFAR1GHSR
SCHEMBL3289538 0.87 KEAP1 (0.40) MEN1KMT2AAPPFFAR1GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341753-B1 CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI AVENTIS (FR) 2007-09-26 EP disclosed
EP-1242083-B1 PHENOXYPROPANOLAMINES, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI AVENTIS (FR) 2007-03-14 EP disclosed
US-6867220-B2 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2005-03-15 US disclosed
US-20030040530-A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them SANOFI-AVENTIS (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040530-A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them CNR1, CORO1C, CBR1 MEN1 3014/4885KMT2A 2208/4885AR 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.